FASENRA approved for treatment of children aged 6 to 11 with severe asthma
TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
- TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
- The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
- Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study).
- Severe uncontrolled asthma in children: practical approach on diagnosis and management.